Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.